234 related articles for article (PubMed ID: 12325066)
1. Gliomatosis cerebri: molecular pathology and clinical course.
Herrlinger U; Felsberg J; Küker W; Bornemann A; Plasswilm L; Knobbe CB; Strik H; Wick W; Meyermann R; Dichgans J; Bamberg M; Reifenberger G; Weller M
Ann Neurol; 2002 Oct; 52(4):390-9. PubMed ID: 12325066
[TBL] [Abstract][Full Text] [Related]
2. Alterations of cell cycle regulators in gliomatosis cerebri.
Mawrin C; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Mawrin A; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Mawrin A; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Mawrin A; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Deimling A; Stoltenburg-Didinge G; Bornemann A; Romeike B; Sellhaus B; Dietzmann K
J Neurooncol; 2005 Apr; 72(2):115-22. PubMed ID: 15925990
[TBL] [Abstract][Full Text] [Related]
3. Genetic profile of gliosarcomas.
Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
[TBL] [Abstract][Full Text] [Related]
4. Analysis of TP53 and PTEN in gliomatosis cerebri.
Mawrin C; Kirches E; Schneider-Stock R; Scherlach C; Vorwerk C; Von Deimling A; Van Landeghem F; Meyermann R; Bornemann A; Müller A; Romeike B; Stoltenburg-Didinger G; Wickboldt J; Pilz P; Dietzmann K
Acta Neuropathol; 2003 Jun; 105(6):529-36. PubMed ID: 12734658
[TBL] [Abstract][Full Text] [Related]
5. Gliomatosis cerebri: post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide.
Mawrin C; Aumann V; Kirches E; Schneider-Stock R; Scherlach C; Vogel S; Mittler U; Dietzmann K; Krause G; Weis S
J Neurooncol; 2001 Oct; 55(1):11-7. PubMed ID: 11804278
[TBL] [Abstract][Full Text] [Related]
6. Pediatric Gliomatosis Cerebri: A Review of 15 Years.
George E; Settler A; Connors S; Greenfield JP
J Child Neurol; 2016 Mar; 31(3):378-87. PubMed ID: 26239491
[TBL] [Abstract][Full Text] [Related]
7. Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas.
Cheng Y; Pang JC; Ng HK; Ding M; Zhang SF; Zheng J; Liu DG; Poon WS
Histopathology; 2000 Nov; 37(5):437-44. PubMed ID: 11119125
[TBL] [Abstract][Full Text] [Related]
8. Gliomatosis cerebri: clinical characteristics, management, and outcomes.
Chen S; Tanaka S; Giannini C; Morris J; Yan ES; Buckner J; Lachance DH; Parney IF
J Neurooncol; 2013 Apr; 112(2):267-75. PubMed ID: 23341100
[TBL] [Abstract][Full Text] [Related]
9. Histological and genetic diagnosis of gliomatosis cerebri: case report.
Yamada SM; Hayashi Y; Takahashi H; Teramoto A; Matsumoto K; Yamada S
J Neurooncol; 2001 May; 52(3):237-40. PubMed ID: 11519853
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
11. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
Seiz M; Tuettenberg J; Meyer J; Essig M; Schmieder K; Mawrin C; von Deimling A; Hartmann C
Acta Neuropathol; 2010 Aug; 120(2):261-7. PubMed ID: 20514489
[TBL] [Abstract][Full Text] [Related]
12. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
[TBL] [Abstract][Full Text] [Related]
13. Gliomatosis cerebri: neurobehavioral and neuropathological observations.
Filley CM; Kleinschmidt-DeMasters BK; Lillehei KO; Damek DM; Harris JG
Cogn Behav Neurol; 2003 Sep; 16(3):149-59. PubMed ID: 14501536
[TBL] [Abstract][Full Text] [Related]
14. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
Biernat W; Debiec-Rychter M; Liberski PP
Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
[TBL] [Abstract][Full Text] [Related]
15. [Gliomatosis cerebri].
Sanson M; Napolitano M; Cartalat-Carel S; Taillibert S
Rev Neurol (Paris); 2005 Feb; 161(2):173-81. PubMed ID: 15798516
[TBL] [Abstract][Full Text] [Related]
16. Genetic aberrations in gliomatosis cerebri support monoclonal tumorigenesis.
Kros JM; Zheng P; Dinjens WN; Alers JC
J Neuropathol Exp Neurol; 2002 Sep; 61(9):806-14. PubMed ID: 12230327
[TBL] [Abstract][Full Text] [Related]
17. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma.
Fulci G; Labuhn M; Maier D; Lachat Y; Hausmann O; Hegi ME; Janzer RC; Merlo A; Van Meir EG
Oncogene; 2000 Aug; 19(33):3816-22. PubMed ID: 10949938
[TBL] [Abstract][Full Text] [Related]
18. [Gliomatosis cerebri].
Masuoka J; Tabuchi K
Nihon Rinsho; 2005 Sep; 63 Suppl 9():128-32. PubMed ID: 16201512
[No Abstract] [Full Text] [Related]
19. Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas.
Kaulich K; Blaschke B; Nümann A; von Deimling A; Wiestler OD; Weber RG; Reifenberger G
J Neuropathol Exp Neurol; 2002 Dec; 61(12):1092-9. PubMed ID: 12484572
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetics of radiographically defined de novo glioblastoma multiforme.
Tortosa A; Ino Y; Odell N; Swilley S; Sasaki H; Louis DN; Henson JW
Neuropathol Appl Neurobiol; 2000 Dec; 26(6):544-52. PubMed ID: 11123721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
